LIPC and End Stage Liver Disease: Patients with cirrhotic end-stage liver disease have lower levels of circulating LCAT, besides alterations in CETP and HL activities [9], which raises the possibility that defective lipoprotein remodeling and catabolism may contribute to the generation of LP-Z in cirrhosis [9,49].